ArticleOncogene2004
The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 85 citations in OpenAlex.
- Mechanism and function of CEACAM1 splice isoforms.European journal of clinical investigation · 2024Review
- Structural aspects of CEACAM1 interactions.European journal of clinical investigation · 2024Review
- Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse?European journal of clinical investigation · 2024Review
- CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens.Genes & cancer · 2023Review
- The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer.Frontiers in immunology · 2023Review
- Article
- Structural basis of the dynamic human CEACAM1 monomer-dimer equilibrium.Communications biology · 2021Article
- Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice.Metabolism: clinical and experimental · 2020Article
- Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer.Scientific reports · 2019Article
- Comparative analysis of CEACAM1 expression in thin melanomas with and without regression.Oncology letters · 2019Article
- CEACAM1 structure and function in immunity and its therapeutic implications.Seminars in immunology · 2019Review
- Characterization of murine CEACAM1Oncotarget · 2018Article
- Article
- Correlation between immunohistochemical staining of CEACAM1 and clinicopathological findings in oral pre-neoplastic lesions and squamous cell carcinoma.Medical molecular morphology · 2018Article
- On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies.Journal of immunology research · 2018Review
- Inhibition of cell invasion and migration by CEACAM1-4S in breast cancer.Oncology letters · 2017Article
- The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches.Gastroenterology research and practice · 2017Review
- Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology.PloS one · 2017Article
- Loss of CEACAM1, a Tumor-Associated Factor, Attenuates Post-infarction Cardiac Remodeling by Inhibiting Apoptosis.Scientific reports · 2016Article
- A Hybrid One-Way ANOVA Approach for the Robust and Efficient Estimation of Differential Gene Expression with Multiple Patterns.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defects in the adenomatous polyposis coli (APC) tumor suppressor pathway are sufficient for neoplastic transformation as the initiating step in colorectal carcinogenesis. In contrast, hyperplastic tumors possess normal APC function, and it is unclear whether they represent significant precursor lesion in cancer development. CEACAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. We found that loss of CEACAM1 expression is more common in neoplastic tumors than APC mutations. While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. In vitro, CEACAM1 acts as a regulator of apoptosis in CEACAM1-transfected Jurkat cells. Finally, in human HT29 colon cancer cells, apoptosis can be specifically restored by induction of CEACAM1 expression. These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.